This month we’re excited to feature an article from the lab of Hafiz Ahmed and others at the University of Maryland, School of Medicine involving the treatment of PC-3 prostate cancer cells with tunicamycin. The article was published 15 July 2017 in the journal Oncotarget and includes gene expression data generated by the Phalanx Biotech […]
OneArray® Research Highlight: Mechanisms of Adipocyte-Mediated Breast Cancer Progression – Nature Communications
This month’s featured article is from the lab of Wen-Hwa Lee at China Medical University in Taiwan and colleagues at National Taiwan University. The article about breast cancer research was published 10 Mar 2017 in the journal Nature Communications. This study focused on adipocytes in the mammary glands and their role in breast cancer tumor […]
OneArray® Research Highlight: How Lung Cancer Cells Immediately Respond to Targeted Therapy and Thereby Develop Drug Resistance
This month’s featured article is from the lab of John T-A Hsu of National Chiao Tung University in Hsinchu, Taiwan. The article regarding research on lung cancer cells was published 19 May 2016 in the journal OncoTargets and Therapy. This study investigates how non-small cell lung cancers (NSCLC) develop resistance to therapies that target epidermal […]
OneArray® Research Highlight: The Mechanisms of Activity of a Milk-Derived Anti-Cancer Fusion Peptide
This month’s featured article is from the lab of Yide Qin of Anhui Medical University in Hefei, China. The article was published 24 March 2016 in the journal BMC Cancer. This study investigates the anti-cancer function and mechanisms of action of a milk-derived anti-cancer fusion peptide (ACFP). The authors built off of previous research into […]
OneArray® Research Highlight: A Novel Molecular Therapeutic Targeting Hepatocellular Carcinoma
This month’s featured article is from a research group led by Pei-Ming Yang at Mackay Memorial Hospital in Taipei, Taiwan. The article was published on 29 January 2016 in the journal Oncoscience. This study investigates the potential of GSK343, an inhibitor to EZH2, as a molecular therapeutic for hepatocellular carcinoma (HCC), which is the third […]